Three-drug therapy helps women with aggressive breast cancer live longer
The treatment could also delay the need for gruelling chemotherapy, according to a trial.
Researchers are hopeful the combination could become the 'new go-to option' for women with PIK3CA-mutated hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
This mutation in the PIK3CA gene causes cells to divide and replicate uncontrollably.
The final results from the INAVO120 study, led by experts at The Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust, have been published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The trial included 325 patients from across 28 countries.
More than half had metastatic breast cancer that had spread to three or more organs and the majority had already had chemotherapy.
Researchers used a blood test known as a liquid biopsy, which detects tumour DNA in the blood, to test for the PIK3CA mutation.
Of the total, 161 were given a three-drug combination comprising two targeted drugs – palbociclib, a type of cancer growth blocker, and a new drug called inavolisib, which blocks the activity of the PI3K protein – as well as the hormone therapy fulvestrant.
The placebo group, which included 164 patients, was given a dummy pill plus palbociclib and fulvestrant.
The study found the median overall survival in the inavolisib group was 34 months, compared with 27 months in the placebo group.
The three-drug therapy also delayed disease progression by 17.2 months, compared with 7.3 months in the placebo group, with patients also able to delay chemotherapy treatment by almost two years longer.
The latest results come after previous analysis of the study, published in October, showed the three-drug therapy delayed disease progression by an average of 15 months compared with 7.3 months in the placebo group.
Lead author Nick Turner, a professor of molecular oncology at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: 'The key findings from this study showed that the inavolisib-based therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened.
'It also gave them more time before needing subsequent chemotherapy which we know is something that patients really fear and want to delay for as long as possible.
'These results give us confidence that this treatment could become the new go-to option for patients who have HR+, HER2- breast cancer with a PIK3CA mutation, as it has shown significant improvements in both survival and quality of life.'
It is estimated that about 55,000 women are diagnosed with breast cancer in the UK every year, some 70% of whom will have HR+, HER2- breast cancer.
PIK3CA mutations are found in 35-40% of HR+ breast cancers.
The three-drug therapy of inavolisib, palbociclib and fulvestrant is not approved in the UK.
However, the combination of palbociclib and fulvestrant has been available as an option for patients with certain types of breast cancer on the NHS since 2022.
Prof Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'If we are to continue improving cancer survival rates, we need to tackle treatment resistance head on.
'This research demonstrates how this triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer.
'One of the challenges with combination therapies is ensuring the right drug dosages and understanding their individual effects.
'It is extremely encouraging that this study not only demonstrates the effectiveness of this approach but also shows that the therapy was generally well tolerated by patients.'
Reacting to the findings, Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: 'This is a significant breakthrough and we're proud that it builds on a series of discoveries that our funded scientists have been making at the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, since it opened 25 years ago.
'We now hope to see this new combination therapy can be licensed by the MHRA (Medicines and Healthcare Products Regulatory Agency) and assessed by Nice (the National Institute for Health and Care Excellence) and the Scottish Medicine Council as soon as possible so that it can reach the NHS patients who could benefit from it.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
4 days ago
- Scottish Sun
We've spent thousands on ‘Mounjaro makeovers' – it's the king of fat jabs but it left us with shocking side effect
WITH Mounjaro users shedding nearly double the amount of weight compared to its other counterparts, it's no wonder the injection is being dubbed the 'king' of fat jabs. But with such drastic results, it's becoming all too common for users to experience side effects they may never have expected - and when that happens, you get yourself booked in for a £10,000 'Mounjaro makeover'. 8 Abbie Rose, 28, started taking Mounjaro in December but was stunned at the shocking side effect 8 Abbie says the fat jab helped her achieve her dream body - but she still had to go under the knife 8 Claire Wilson, stomach pictured, was left with an abundance of loose skin after losing three stone on Mounjaro After injecting the wonder drug for mere months and watching the weight drop off stone by stone, Brits up and down the country are feeling healthier and sexier. But when the fat is gone and all but stretched skin remains, many will feel disheartened at not having achieved their dream body with a quick fix. Mounjaro users are more likely to experience saggy, excess skin compared to those using other brands of fat jabs because of rapid weight loss, according to cosmetic surgeons. Mum-of-three Claire Wilson was one of them - shedding three stone on Mounjaro, she was left with an abundance of loose skin around her middle, which she just couldn't stomach. She told The Sun how the fat jab completely changed her life when she hit 13st after turning 40. But it wasn't the end of her weight loss journey as she'd hoped - and she decided to go under the knife for a £10,000 'Mounjaro makeover' to achieve her dream figure. The makeover is a combination of cosmetic procedures sought by patients to remove excess skin after rapid weight loss. Claire had four pounds of flabby skin removed, finally hit her goal weight of 9st and cried with joy when she looked in the mirror for the first time. The 43-year-old from Swansea told Fabulous: 'I've spent decades hating my body. 'But I burst into tears the second I saw my new, flat stomach. Mounjaro Weight Loss injection from Ozeias Se Silva Known As Ozzy Tudo 'I used to hate my reflection and looking at myself but the second I had the surgery and saw how different I looked, I just couldn't believe it. It's changed my life.' 'King' of fat jabs Mounjaro - dubbed the "King Kong" of weight loss jabs - helped people shed significantly more weight than it's rival Wegovy, research published in the New England Journal of Medicine found. Though both drugs were effective for weight loss, Mounjaro not only helped people shed more pounds, but they also lost more inches around their waist. Mounjaro's active ingredient is tirzepatide, while Wegovy's is semaglutide - the same active drug in diabetes jab Ozempic. One study, by weight loss programme Second Nature, found that Mounjaro users experienced a 21.4% reduction in body weight, while Ozempic patients saw a 11.2% reduction over a 40 week period. I've had three children so like lots of mums I ended up with loose skin but losing weight on Mounjaro it became even more evident. Claire Wilson Dr Darren Smith, a New York cosmetic surgeon, explained how the rapid weight loss from Mounjaro can contribute to excess skin laxity. Explaining the trend, which is rising in popularity in the US, he told his Instagram followers: 'The term 'Mounjaro Makeover' is increasingly popular, and this is a term I use to describe any combination of operations that we're performing to help you get rid of extra skin that you're seeing after weight loss with Mounjaro. 'In many cases, patients that are using Mounjaro and losing a significant amount of weight over a very short period of time might experience even more significant skin laxity than patients that are doing it with Ozempic. 'Patients on Mounjaro are often achieving nearly bariatric surgical levels of weight loss, and these patients are having operations similar to those patients after bariatric surgery to get rid of extra skin.' 'I hated my excess skin' Claire weighed 13st at her heaviest and while she would have liked to work off her weight gain in the gym, like she had done in the past, she noticed her metabolism slowed down when she hit 40. She says: 'I've gained and lost around three stone three or four times in my life. 'I'd ended up around 13st but I'm only 5ft 2in and when I tried to exercise and diet the weight off this time around, I simply couldn't.' Claire began researching fat jabs and decided to try Mounjaro. She added: 'I saw so many people on social media losing over 9lbs a week. I was keen to try it for myself.' Claire started using the jabs in May 2024 and the weight began to drop away at a rapid rate. 8 Mum-of-three Claire, stomach pictured, spent thousands on a 'Mounjaro Makeover' and had four pounds of flabby skin chopped off 8 Like Claire, Abbie also had a makeover which consisted of a tummy tuck, muscle repair and liposuction 8 Abbie reveals she was 'over the moon' after seeing the results of her makeover She says: 'It was amazing. It totally changed my appetite. I was on a 2.5mg dose to begin with, which went up to 5mg. That was my maximum dose which I'm still on now. It's a maintenance dose I take every two weeks to keep my appetite low." But by September of that year, she noticed that her excess skin was becoming an issue. 'I've had three children so like lots of mums I ended up with loose skin but losing weight on Mounjaro it became even more evident,' she says. 'I absolutely hated it, which is when I started thinking about a Mounjaro makeover. 'I spent over £1,000 on Mounjaro and then saved £10,000 to have tummy tuck surgery. 'I hated the excess skin and what I looked like, my self-esteem was terrible and it affected every area of my life.' Claire's surgery last month - after she hit her target weight of nine stone - was the culmination of 13 months of weight loss. I'm so happy with the new body I have, getting rid of my flabby tummy has changed my life Claire Wilson Her surgeon, Iain Whitaker; professor of Plastic Surgery, and The Welsh Representative on BAAPS Council, performed a 'fleur de lys' surgery with a horizontal and vertical incision before removing around 4lbs(1.75kg) of Claire's excess skin. She says: 'I couldn't believe the amount of skin they removed, there was so much, the video (taken by the medical team) was incredible when I first saw it, around 1.75kg of skin was removed. 'I've been in a bit of discomfort but the recovery has been incredible. I'm still bound at the moment to help reduce scarring but then the surgery was only recently. 'My recovery is ongoing but I'm so happy with the new body I have, getting rid of my flabby tummy has changed my life.' Claire says she can't wait to get into a bikini this summer. She adds: 'It's incredible how much my confidence has changed. 'Having a Mounjaro makeover has completely changed how I feel about myself. I feel sexier than I have in years and have had loads of compliments from friends.' 'Easy way out' Meanwhile, Abbie Rose, 28, started taking Mounjaro in December and credits it with helping her achieve her dream body. The mum of three from Shropshire says: 'I was a size 12 and weighed 11 stone 9lbs. 'I think there can be some negativity around weight loss injections but they're amazing. 'I think if they help people and give them their confidence back, that's amazing.' But, like Claire, she was left with extra skin around her stomach, so she booked in with Professor Whitaker to help her hit her ideal weight of 9st 7lbs. She says: 'My Mounjaro makeover consisted of a tummy tuck, muscle repair and liposuction, it was £9,000. 'It was uncomfortable but manageable when it came to the pain and the recovery. I was over the moon when I first saw my results. The Mounjaro Makeover can remove skin from anywhere with the most common areas being the abdomen, arms, breasts, or thighs – or a combination Professor Whitaker 'I spent £300 on Mounjaro injections and the Mounjaro makeover isn't something I went into with my eyes closed. 'I spoke to lots of friends and family about it and they were supportive of my decision and knew it was something I had wanted for a long time, around seven years.' Claire agrees - despite having received negativity, she says she simply couldn't have achieved the body she has now by exercise and diet alone. She told The Sun: 'It's easy for people to say Mounjaro and Mounjaro makeovers are cheating and are the easy way out. 'But I've battled with my weight for years and, thanks to the injections and Professor Whitaker, I'm at the exact weight I want to be, and I have a body I've always dreamed of having.' Professor Whitaker says a patient should be at or near their target weight, with a BMI around 25 or lower, before considering surgery. He says: 'That ensures the skin is looser and the fat thickness is reduced, which reduces tension on the closure, better blood supply, reduced complications and leads to better results. 8 She took the plunge once she hit her ideal weight of 9st 7lbs 8 Abbie says her friends and family were supportive of her choice to get the makeover 'Surgery is most successful when the weight is stable. Some people may still have a bit to lose post-surgery, but they've already done the hard work.' He adds: 'The hashtag #mounjaromakeover started in the US but like a lot of trends, it's come to the UK. Now dozens of women have shared their Moujaro makeovers online." Mounjaro is approved for weight loss in the UK, while Ozempic is only approved for type 2 diabetes. Gemma Collins and Jeremy Clarkson are two of the Brit stars who have admitted using Mounjaro, while Sharon Osbourne, Amy Schumer and Oprah Winfrey have discussed their Ozempic journeys. Prof Whitaker adds: 'The Mounjaro Makeover can remove skin from anywhere with the most common areas being the abdomen, arms, breasts, or thighs – or a combination. 'Each has its pros and cons, but the abdomen is by far the most common and the area I'm asked for when it comes to Mounjaro Makeovers the most.' Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Prof Whitaker says surgery after large weight loss on Mounjaro is honestly the only option. 'The reality is, once you've lost that kind of weight, no matter what anyone says, it's unlikely you can bring the abdominal muscles back together through physio or exercise alone. And you certainly can't remove the excess skin without surgery. 'The idea that injections, lasers, suction, or radiofrequency devices can meaningfully tighten that skin after this volume of weight loss is, frankly, complete nonsense. 'None of those approaches are effective for the kind of skin laxity we're talking about here. The only real solution is surgery.'
BBC News
6 days ago
- BBC News
Leeds researchers hail leukaemia treatment 'milestone'
A chemotherapy-free approach for some patients suffering from leukaemia could lead to better outcomes, scientists behind a five-year medical trial have findings of the UK-wide study, led by researchers from Leeds, could reshape the way the most common form of leukaemia in adults was treated, according to those behind the trial looked at whether using two targeted cancer drugs could prove to be more effective than standard chemotherapy among patients with chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in Talha Munir, consultant haematologist at Leeds Teaching Hospitals NHS Trust, who led the study, called its results a "milestone". CLL is a rare blood cancer that affects about 3,800 people in the UK each year, most of whom are over the age of 40. Symptoms can include persistent illness, weight loss, swelling, fatigue and anaemia, where there are not enough red blood cells in the blood. The half-decade-long trial involved researchers from Leeds Teaching Hospitals NHS Trust and the University of Leeds and focused on 786 patients across 96 cancer results showed that the treatment, using two drugs, ibrutinib and venetoclax, led to better survival rates, fewer long-term side effects, and the possibility of life without chemotherapy for many to the results of the study, which have now been published in the New England Journal of Medicine, researchers also found the alternative treatment regime was tolerated better than traditional Munir said: "We have shown a chemotherapy-free approach can be not only more effective but also more tolerable for patients."By tailoring individualised treatment based on how well the cancer responds, we're moving into an era of truly personalised medicine." One of the patients benefiting from the trial was Catherine Whitfield, from Farnley, Leeds, who was diagnosed with CLL in 2018 and who now has no cancer cells after three years of Whitfield, 63, said the trial had "felt right" to her. "The way this trial was explained, it just made sense," she explained. "Also, the thought of chemotherapy was scary to me. The trial felt right. And it was."Ms Whitfield said she had previously lost her husband to cancer: "I have seen how hard it could be.""My first thought after my diagnosis was, I will never see my grandchildren being born and growing up," she said."Now I have two grandchildren, Drew and Alaia, and they are a delight and highlight the joys of a healthy life".Dr Munir said: "This isn't just about data. It's about people like Catherine, and thousands of others, who trusted us with their care. "Thanks to them, we're changing the future of cancer treatment." Listen to highlights from West Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
ITV News
7 days ago
- ITV News
New leukaemia treatment hailed as ‘milestone' for patients
Scientists have hailed a 'milestone' in leukaemia care for patients after a UK trial found a chemotherapy-free approach to treatment may lead to better outcomes for some patients. The groundbreaking UK-wide trial could reshape the way the most common form of leukaemia in adults is treated. Researchers from Leeds wanted to assess whether two targeted cancer drugs could perform better than standard chemotherapy among patients with chronic lymphocytic leukaemia (CLL). They led the Flair trial, which took place at 96 cancer centres across the UK. Flair trial is a milestone. We have shown that a chemotherapy-free approach can be not only more effective but also more tolerable for patients Dr Talha Munir Some 786 people with previously untreated CLL were randomly assigned to receive standard chemotherapy; a single targeted drug, ibrutinib, or two targeted drugs taken together, ibrutinib and venetoclax, with treatment guided by personalised blood tests. They found that after five years, 94% of patients who received ibrutinib plus venetoclax were alive with no disease progression. This compares with 79% for those on ibrutinib alone and 58% for those on standard chemotherapy, according to the study, which has been published in the New England Journal of Medicine and presented to the European Haematology Association congress in Milan, Italy. Meanwhile 66% of patients on the new combination had no detectable cancer in their bone marrow after two years, compared with none of the people who received ibrutinib alone and 48% on chemotherapy. Ibrutinib is a type of drug known as a cancer growth blocker. It works by stopping signals that cancer cells use to divide and grow. And venetoclax blocks the functions of a protein found in CLL cells. Experts said that the new treatment regime was also tolerated better than traditional treatments. Dr Talha Munir, consultant haematologist at Leeds Teaching Hospitals NHS Trust, who led the study said: 'Flair trial is a milestone. 'We have shown that a chemotherapy-free approach can be not only more effective but also more tolerable for patients. 'By tailoring individualised treatment based on how well the cancer responds, we're moving into an era of truly personalised medicine.' Catherine Whitfield, 63, from Farnley, West Yorkshire, was diagnosed with CLL in 2018 after she noticed symptoms including bleeding gums, constant illness and neck pain. She signed up to the trial, which was co-ordinated by the Leeds Cancer Research UK Clinical Trials Unit at the University of Leeds and sponsored by the University of Leeds. She said: 'After three years of treatment, I am still MRD negative – that means no cancer cells.' 'I lost my husband to cancer. I have seen how hard it could be. 'My first thought after my diagnosis was, I will never see my grandchildren being born and growing up. 'Now I have two grandchildren, Drew and Alaia, and they are a delight and highlight the joys of a healthy life'. Ms Whitfield added: 'The way this trial was explained, it just made sense. 'Also, the thought of chemotherapy was scary to me. The trial felt right. And it was.' Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, which funded the trial along with AbbVie, and Johnson and Johnson, said: 'The results of the Flair trial show that we can provide kinder, more targeted treatment for chronic lymphocytic leukaemia, which gives people with CLL more precious time with their loved ones. 'We're hopeful that the results of the Flair trial will power new treatment options for leukaemia and other blood cancers, thanks to the efforts of researchers at in Leeds and across the UK working together on this trial.' Chronic lymphocytic leukaemia is the most common form of leukaemia in adults. There are about 4,000 new CLL cases in the UK every year.
